Sanofi Acomplia obesity NDA likely to see action by April
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis submitted a complete response to FDA's Feb. 17 "approvable" letter for an obesity indication for Acomplia (rimonabant) on Oct. 26. Class 2 designation for the submission would carry an April 26, 2007, user fee date; Class 1 designation would hold the potential of action by year-end...